Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting home-clinic blood pressure differences.

Journal of the American Society of Hypertension : JASH·2016
Same author

ARAs to the RESCUE.

Journal of the American Society of Hypertension : JASH·2016
Same author

Poor Choices of Antihypertensive Drugs.

Journal of the American Society of Hypertension : JASH·2016
Same author

Home Monitoring in the US: Its About Time.

Journal of the American Society of Hypertension : JASH·2016
Same author

THE GROWING PROBLEM OF OBESITY.

Journal of the American Society of Hypertension : JASH·2016
Same author

SOME GOOD EPIDEMIOLOGIC NEWS.

Journal of the American Society of Hypertension : JASH·2016
Same journal

The origin of clinical left ventricular ejection fraction measurement.

Nature reviews. Cardiology·2026
Same journal

Inclusive cardiovascular care for sexual and gender minority populations.

Nature reviews. Cardiology·2026
Same journal

Modular cardiac microtissues for interrogating cell-type contributions.

Nature reviews. Cardiology·2026
Same journal

Sleep and exercise can limit clonal haematopoiesis clone expansion and reduce associated atherosclerosis.

Nature reviews. Cardiology·2026
Same journal

Epigenetic regulation in atherosclerosis and its therapeutic potential.

Nature reviews. Cardiology·2026
Same journal

Coronary artery calcium on chest CT scans: from incidental finding to mandatory reporting.

Nature reviews. Cardiology·2026
See all related articles

Related Experiment Video

Updated: Jun 24, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Combination therapy for hypertension.

Norman M Kaplan1

  • 1University of Texas Southwestern Medical School, Dallas, TX 75390, USA. norman.kaplan@utsouthwestern.edu

Nature Reviews. Cardiology
|April 9, 2009
PubMed
Summary
This summary is machine-generated.

Most patients need multiple drugs for hypertension. Combining a renin-angiotensin inhibitor with a long-acting calcium-channel blocker offers superior cardiovascular protection compared to diuretic-based regimens.

Related Experiment Videos

Last Updated: Jun 24, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Nephrology

Background:

  • Hypertension management often requires combination therapy.
  • Diuretic-based regimens are common but may not be optimal.
  • Renin-angiotensin inhibitors and calcium-channel blockers are key antihypertensive classes.

Discussion:

  • Two large trials compared different antihypertensive drug combinations.
  • Outcomes focused on cardiovascular protection.
  • The study evaluated the efficacy of renin-angiotensin inhibitor/calcium-channel blocker versus diuretic-based therapies.

Key Insights:

  • Combination therapy with a renin-angiotensin inhibitor and a long-acting calcium-channel blocker provides enhanced cardiovascular protection.
  • This combination is superior to regimens including a diuretic for cardiovascular outcomes.
  • Evidence supports a shift in preferred combination strategies for hypertension.

Outlook:

  • Future hypertension guidelines may favor renin-angiotensin inhibitor/calcium-channel blocker combinations.
  • Further research could explore long-term benefits and specific patient populations.
  • Optimizing combination therapy is crucial for reducing cardiovascular morbidity and mortality.